ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för desferrioxamine B mesylate. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

22 träffar

Bibliografisk träff 2021-01-07

Intraperitoneal injection of Desferal® alleviated the age-related bone loss and senescence of bone marrow stromal cells in rats.

Yi L, Ju Y, He Y, Yin X, Xu Y, Weng T.

Stem Cell Res Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13287-020-02112-9

Bibliografisk träff 2020-11-20

Deferoxamine mesylate improves splicing and GAA activity of the common c.-32-13T>G allele in late-onset PD patient fibroblasts.

Buratti E, Peruzzo P, Braga L, Zanin I, Stuani C, Goina E, Romano M, Giacca M, Dardis A.

Mol Ther Methods Clin Dev · research-article; journal article · DOI 10.1016/j.omtm.2020.11.011

Bibliografisk träff 2020-03-07

Formulation and In-Vitro Characterization of Chitosan-Nanoparticles Loaded with the Iron Chelator Deferoxamine Mesylate (DFO).

Lazaridou M, Christodoulou E, Nerantzaki M, Kostoglou M, Kostoglou M, Lambropoulou DA, Katsarou A, Pantopoulos K, Bikiaris DN.

Pharmaceutics · research-article; journal article · DOI 10.3390/pharmaceutics12030238

Bibliografisk träff 2019-12-02

A combination of Deferoxamine mesylate and minimally invasive surgery with hematoma lysis for evacuation of intracerebral hemorrhage.

Pandey AS, Daou BJ, Chaudhary N, Xi G.

J Cereb Blood Flow Metab · article-commentary; review; journal article · DOI 10.1177/0271678x19892660

Bibliografisk träff 2019-08-01

Preparation and optimization of polymeric micelles as an oral drug delivery system for deferoxamine mesylate: <i>in vitro</i> and <i>ex vivo</i> studies.

Salimi A, Sharif Makhmal Zadeh B, Kazemi M.

Res Pharm Sci · research-article; journal article · DOI 10.4103/1735-5362.263554

Bibliografisk träff 2019-03-18

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.

Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD, i-DEF Investigators.

Lancet Neurol · clinical trial, phase ii; research-article; multicenter study; journal article; research support, n.i.h., extramural · DOI 10.1016/s1474-4422(19)30069-9

Bibliografisk träff 2017-07-19

Effects of Deferoxamine Mesylate on Hematoma and Perihematoma Edema after Traumatic Intracerebral Hemorrhage.

Yu J, Yuan Q, Sun YR, Wu X, Du ZY, Li ZQ, Wu XH, Zhou LF, Wu G, Hu J.

J Neurotrauma · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1089/neu.2017.5033

Bibliografisk träff 2016-08-01

Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo.

Chen SJ, Kuo CC, Pan HY, Tsou TC, Yeh SC, Chang JY.

Oncotarget · research-article; journal article · DOI 10.18632/oncotarget.10336

Bibliografisk träff 2016-07-29

Preventive effect of Desferal on sperm motility and morphology.

Nenkova G, Stefanov R, Chervenkov M, Alexandrova A.

Cell Biochem Funct · journal article · DOI 10.1002/cbf.3203

Bibliografisk träff 2016-06-13

Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis.

Jiang L, Chew SH, Nakamura K, Ohara Y, Akatsuka S, Toyokuni S.

Cancer Sci · research-article; journal article · DOI 10.1111/cas.12947

Bibliografisk träff 2015-04-13

The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage.

Yu Y, Zhao W, Zhu C, Kong Z, Xu Y, Liu G, Gao X.

PLoS One · research-article; randomized controlled trial; journal article · DOI 10.1371/journal.pone.0122371

Bibliografisk träff 2015-01-22

Solid microparticles based on chitosan or methyl-β-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate.

Rassu G, Soddu E, Cossu M, Brundu A, Cerri G, Marchetti N, Ferraro L, Regan RF, Giunchedi P, Gavini E, Dalpiaz A.

J Control Release · research-article; journal article · DOI 10.1016/j.jconrel.2015.01.025

Bibliografisk träff 2014-09-22

Deferoxamine mesylate enhances virulence of community-associated methicillin resistant Staphylococcus aureus.

Arifin AJ, Hannauer M, Welch I, Heinrichs DE.

Microbes Infect · research support, non-u.s. gov't; journal article · DOI 10.1016/j.micinf.2014.09.003

Bibliografisk träff 2013-08-21

Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.

Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.

Cochrane Database Syst Rev · meta-analysis; research support, non-u.s. gov't; systematic review; systematic-review; journal article · DOI 10.1002/14651858.cd004450.pub3

Bibliografisk träff 2012-12-01

Desferal as improving agent for hemoglobin fructation: structural and functional impacts.

Sattarahmady N, Heli H, Moosavi-Movahedi AA.

Protein J · research support, non-u.s. gov't; journal article · DOI 10.1007/s10930-012-9444-3

Bibliografisk träff 2011-08-25

Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage.

Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y, Deferoxamine Mesylate in Intracerebral Hemorrhage Investigators.

Stroke · comparative study; research-article; multicenter study; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1161/strokeaha.111.617589

Bibliografisk träff 2011-06-01

Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation in rats.

Li Y, Zhang PJ, Jin C, Zhou B, Liu XY, Tao LD, Feng M.

Transplant Proc · research support, non-u.s. gov't; journal article · DOI 10.1016/j.transproceed.2010.09.176

Bibliografisk träff 2010-10-19

The effects of deferoxamine mesylate on iron elimination after blood transfusion in neonatal foals.

Elfenbein JR, Giguère S, Meyer SK, Javsicas LH, Farina LL, Zimmel DN, Sanchez LC.

J Vet Intern Med · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1939-1676.2010.0621.x

Bibliografisk träff 2010-06-01

Deferoxamine mesylate is toxic for retinal pigment epithelium cells in vitro, and its toxicity is mediated by p38.

Klettner A, Koinzer S, Waetzig V, Herdegen T, Roider J.

Cutan Ocul Toxicol · journal article · DOI 10.3109/15569521003745685

Bibliografisk träff 2009-12-10

Treatment with the iron chelator, deferoxamine mesylate, alters serum markers of oxidative stress in stroke patients.

Selim M.

Transl Stroke Res · journal article · DOI 10.1007/s12975-009-0001-0

Bibliografisk träff 2008-12-08

Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.

Selim M.

Stroke · review; journal article; research support, n.i.h., extramural · DOI 10.1161/strokeaha.108.533125

Bibliografisk träff 2007-12-01

Evaluation and management of pediatric patients with anaphylactoid reactions to deferoxamine mesylate.

Somech R, Seaban-Adel K, Atkinson A, Kirby-Allen M.

Ann Allergy Asthma Immunol · letter · DOI 10.1016/s1081-1206(10)60392-4